Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.

• Revenue in DKK (TTM)76.87m
• Net income in DKK-1.05bn
• Incorporated1997
• Employees298.00

• Location
  Zealand Pharma A/SSydmarken 11SOEBORG 2860DenmarkDNK
• Phone+45 88773600
• Fax+45 88773898
• Websitehttps://www.zealandpharma.com/